Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $20,577.15 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 37,413 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $0.55, for a total transaction of $20,577.15. Following the transaction, the director owned 2,198,642 shares in the company, valued at $1,209,253.10. This represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total transaction of $17,451.12.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total transaction of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total transaction of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total value of $15,476.44.

Werewolf Therapeutics Trading Down 0.3%

Shares of NASDAQ:HOWL opened at $0.55 on Friday. The stock’s 50-day simple moving average is $0.83 and its two-hundred day simple moving average is $1.23. The stock has a market capitalization of $26.66 million, a price-to-earnings ratio of -0.34 and a beta of 0.77. Werewolf Therapeutics, Inc. has a 52-week low of $0.53 and a 52-week high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HOWL. Wedbush downgraded shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research report on Friday, December 19th. Citizens Jmp downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Bank of America lowered their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, HC Wainwright reduced their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 19th. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.75.

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the stock. Quadrature Capital Ltd purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at about $28,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics during the second quarter valued at approximately $48,000. AQR Capital Management LLC bought a new position in Werewolf Therapeutics during the first quarter valued at approximately $79,000. Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics during the 2nd quarter valued at approximately $92,000. Finally, Susquehanna International Group LLP increased its stake in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.